Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2026-02-03 @ 11:13 AM
Study NCT ID:
NCT01955460
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-14
First Post:
2013-09-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Melanoma | View |
| None | Stage III Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIA Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIB Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIC Cutaneous Melanoma AJCC v7 | View |
| None | Stage IV Cutaneous Melanoma AJCC v6 and v7 | View |
Keywords: